Superparamagnetic iron oxide nanoparticles stabilized by alginate: Pharmacokinetics, tissue distribution, and applications in detecting liver cancers

International Journal of Pharmaceutics

Volumn 354, Issue 1-2, 2008, Pages 217-226

  Ma, Hui Li ^a   Xu, Yu Feng ^b   Qi, Xian Rong ^a   Maitani, Yoshie ^c   Nagai, Tsuneji ^d  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

^c HOSHI UNIVERSITY   (Japan)

^d Nagai Foundation Tokyo   (Japan)

Author keywords

Alginate; Contrast agent; Distribution; Liver cancers; Pharmacokinetics; Superparamagnetic iron oxide nanoparticles (SPIO)

Indexed keywords

ALGINIC ACID; CONTRAST MEDIUM; NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; HISTOPATHOLOGY; LIVER CELL CARCINOMA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; XENOGRAFT;

ALGINATES; ANIMALS; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FERRIC COMPOUNDS; GLUCURONIC ACID; HALF-LIFE; HEXURONIC ACIDS; INJECTIONS, INTRAVENOUS; KUPFFER CELLS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MALE; NANOPARTICLES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPLEEN; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 40849114851     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.11.036     Document Type: Article

References (36)

1. Bouhadir K.H., Lee K.Y., Alsberg E., Damm K.L., Anderson K.W., and Mooney D.J. Degradation of partially oxidized alginate and its potential application for tissue engineering. Biotechnol. Prog. 17 (2001) 945-950
2. Bourrinet P., Bengele H.H., Bonnemain B., Dencausse A., Idee J.M., Jacobs P.M., and Lewis J.M. Preclinical safety and pharmacokinetic profile of Ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest. Radiol. 41 (2006) 313-324
3. Briley-SæbØ K., Hustvedt S.O., Haldorsen A., and BjØrnerud A. Long-term imaging effects in rat liver after a single injection of an iron oxide nanoparticle based MR contrast agent. J. Magn. Reson. Imaging 20 (2004) 622-631
4. Clement O., Frija G., Chambon C., Schouman-Clayes E., Mosnier J.F., Poupon M.F., and Balkau B. Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging. Radiology 180 (1991) 31-36
5. Corot C., Robert P., Idee J.M., and Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 58 (2006) 1471-1504
6. Gombotz W.R., and Wee S.F. Protein release from alginate matrices. Adv. Drug Deliv. Rev. 31 (1998) 267-285
7. Gupta A.K., and Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26 (2005) 3995-4021
8. Hagar W., Vichinsky E.P., and Theil E.C. Liver ferritin subunit ratios in neonatal hemochromatosis. Pediatr. Hematol. Oncol. 20 (2003) 229-235
9. Harmut-Hoene A., and Schelenz R. Effect of dietary fiber on mineral absorption in growing rats. J. Nutr. 110 (1980) 1774-1784
10. Hauff P., Fritzsch T., Reinhardt M., Weitschies W., Lueders F., Uhlendorf V., and Heldmann D. Delineation of experimental liver tumors in rabbits by a new ultrasound contrast agent and stimulated acoustic emission. Invest. Radiol. 32 (1997) 94-99
11. Hundt W., Petsch R., Helmberger T., and Reiser M. Signal changes in liver and spleen after Endorem administration in patients with and without liver cirrhosis. Eur. Radiol. 10 (2000) 409-416
12. Imai Y., Murakami T., Yoshida S., Nishikawa M., Ohsawa M., Tokunaga K., Murata M., Shibata K., Zushi S., Kurokawa M., Yonezawa T., Kawata S., Takamura M., Nagano H., Sakon M., Monden M., Wakasa K., and Nakamura H. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 32 (2000) 205-212
13. Kellar K.E., Fujii D.K., Gunther W.H.H., Briley-Saebo K., Bjornerod A., Spiller M., and Koenig S.H. Important considerations in the design of iron oxide nanoparticles as contrast agents for T1-weighted MRI and MRA. Acad. Radiol. 9 (2002) S34-S37
14. Kellar K.E., Fujii D.K., Gunther W.H.H., Briley-Saebo K., Bjornerod A., Spiller M., and Koenig S.H. "NC100150 injection," a preparation of optimized iron oxide nanoparticles for positive contrast MR angiography. J. Magn. Reson. Imaging 11 (2000) 488-494
15. Kim J.H., Kim M.J., Suh S.H., Chung J.J., Yoo H.S., and Lee J.T. Characterization of focal hepatic lesions with ferumoxides-enhanced MR imaging: utility of T1-weighted spoiled gradient recalled echo images using different echo times. J. Magn. Reson. Imaging 15 (2002) 573-583
16. Ma H.L., Qi X.R., Maitani Y., and Nagai T. Preparation and characterization of superparamagnetic iron oxide nanoparticles stabilized by alginate. Int. J. Pharma 333 (2007) 177-186
17. Ma H.L., Qi X.R., Ding W.X., Maitani Y., and Nagai T. Magnetic targeting after femoral artery administration and biocompatibility assessment of superparamagnetic iron oxide nanoparticles. J. Biomed. Mater. Res. Part A 84A (2007) 598-606
18. Nakayama M., Kamura T., Kimura M., Seki H., Tsukada K., and Sakai K. Quantitative MRI of hepatocellular carcinoma in cirrhotic and noncirrhotic livers. Clin. Imaging 22 (1998) 280-283
19. Neuberger T., Schöpf B., Hofmann H., Hofmann M., and Von Rechenberg B. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J. Magn. Magn. Mater. 293 (2005) 483-496
20. Oswald P., Clement O., Chambon C., Schouman-Claeys E., and Frija G. Liver positive enhancement after injection of superparamagnetic nanoparticles: respective role of circulating and uptaken particles. Magn. Reson. Imaging 15 (1997) 1025-1031
21. Pouliquen D., Le Jeune J.J., Perdrisot R., Ermias A., and Jallet P. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn. Reson. Imaging 9 (1991) 275-283
22. Reimer P., Rummeny E.J., Daldrup H.E., Balzer T., Tombach B., Berns T., and Peters P.E. Clinical results with resovist: a phase 2 clinical trial. Radiology 195 (1995) 489-496
23. Robitaille R., Pariseau J.F., Leblond F.A., Lamoureux M., Lepage Y., and Hallé J.P. Studies on small (<350 μm) alginate-poly-l-lysine microcapsules. III. Biocompatibility of smaller versus standard microcapsules. J. Biomed. Mater. Res. 44 (1999) 116-120
24. Saini S., Stark D.D., Hahn P.F., Bousquet J.C., Introcasso J., Wittenberg J., Brady T.J., and Ferrucci. Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology 162 (1987) 217-222
25. Seternes T., Oynebraten I., Sorensen K., and Smedsrod B. Specific endocytosis and catabolism in the scavenger endothelial cells of cod (Gadus morhua L.) generate high-energy metabolites. J. Exp. Biol. 204 (2001) 1537-1546
26. Sokov L.A. Radioaktivnye Izotopy Vo Vneshnei Sredei Organizine (1970), Atomizdat, Moscow p. 247
27. Solandt O.M. Some observations upon sodium alginate. Quart. J. Exp. Physiol. 31 (1941) 25-30
28. Tanimoto A., Pouliquen D., Kreft B.P., and Stark D.D. Effects of spatial distribution on proton relaxation enhancement by particulate iron oxide. J. Magn. Reson. Imaging 4 (1994) 653-657
29. Tanimoto A., Oshio K., Suematsu M., Pouliquen D., and Stark D.D. Relaxation effects of clustered particles. J. Magn. Reson. Imaging 14 (2001) 72-77
30. Tanimoto A., Yuasa Y., Shinmoto H., Jinzaki M., Imai Y., Okuda S., and Kuribayashi S. Superparamagetic iron oxide-mediated hepatic signal intensity change in patients with and without cirrhosis: pulse sequence effects and Kupffer cell function. Radiology 222 (2002) 661-666
31. Taupitz M., Wagner S., Schnorr J., Kravec I., Pilgrimm H., Bergmann-Fritsch H., and Hamm B. Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest. Radiol. 39 (2004) 394-405
32. Van Beers B.E., Sempoux C., Materne R., Delos M., and Smith A.M. Biodistribution of ultrasmall iron oxide particles in the rat liver. J. Magn. Reson. Imaging 13 (2001) 594-599
33. Wang Y.X., Hussain S.M., and Krestin G.P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol. 11 (2001) 2319-2331
34. Ward J., Guthrie J.A., Wilson D., Arnold P., Lodge P., Toogood G.J., Wyatt J.I., and Robinson P.J. Colorectal hepatic metastases: detection with SPIO-enhanced breath-hold MR imaging-comparison of optimized sequences. Radiology 228 (2003) 709-718
35. Weinmann H.J., Ebert W., Misselwitz B., and Schmitt-Willich H. Tissue-specific MR contrast agents. Eur. J. Radiol. 46 (2003) 33-44
36. Weissleder R., Stark D.D., Engelstad B.L., Bacon B.R., Compton C.C., White D.L., Jacobs P., and Lewis J. Superparamagnetic iron oxide: pharmacokinetics and toxicity. Am. J. Roentgenol. 152 (1989) 167-173